CA2869295A1 - Procedes faisant appel a la methylation de l'adn pour identifier une cellule ou un melange de cellules afin de pronostiquer et de diagnostiquer des maladies et pour effectuer des traitements de reparation cellulaire - Google Patents
Procedes faisant appel a la methylation de l'adn pour identifier une cellule ou un melange de cellules afin de pronostiquer et de diagnostiquer des maladies et pour effectuer des traitements de reparation cellulaire Download PDFInfo
- Publication number
- CA2869295A1 CA2869295A1 CA2869295A CA2869295A CA2869295A1 CA 2869295 A1 CA2869295 A1 CA 2869295A1 CA 2869295 A CA2869295 A CA 2869295A CA 2869295 A CA2869295 A CA 2869295A CA 2869295 A1 CA2869295 A1 CA 2869295A1
- Authority
- CA
- Canada
- Prior art keywords
- methylation
- dna
- cell
- cells
- cpg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 311
- 230000007067 DNA methylation Effects 0.000 title claims abstract description 135
- 201000010099 disease Diseases 0.000 title claims abstract description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000003745 diagnosis Methods 0.000 title claims description 24
- 238000002560 therapeutic procedure Methods 0.000 title claims description 20
- 238000004393 prognosis Methods 0.000 title claims description 12
- 238000005067 remediation Methods 0.000 title description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 192
- 201000011510 cancer Diseases 0.000 claims abstract description 128
- 210000004369 blood Anatomy 0.000 claims abstract description 116
- 239000008280 blood Substances 0.000 claims abstract description 116
- 238000009826 distribution Methods 0.000 claims abstract description 77
- 230000004075 alteration Effects 0.000 claims abstract description 16
- 210000000265 leukocyte Anatomy 0.000 claims description 318
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 300
- 230000011987 methylation Effects 0.000 claims description 273
- 238000007069 methylation reaction Methods 0.000 claims description 272
- 210000004027 cell Anatomy 0.000 claims description 231
- 108091029430 CpG site Proteins 0.000 claims description 204
- 239000000523 sample Substances 0.000 claims description 193
- 108020004414 DNA Proteins 0.000 claims description 142
- 108090000623 proteins and genes Proteins 0.000 claims description 132
- 238000004458 analytical method Methods 0.000 claims description 115
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 claims description 106
- 210000000822 natural killer cell Anatomy 0.000 claims description 106
- 238000003752 polymerase chain reaction Methods 0.000 claims description 79
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 claims description 77
- 230000017858 demethylation Effects 0.000 claims description 77
- 238000010520 demethylation reaction Methods 0.000 claims description 77
- 210000003714 granulocyte Anatomy 0.000 claims description 77
- 210000003289 regulatory T cell Anatomy 0.000 claims description 77
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 74
- 210000001616 monocyte Anatomy 0.000 claims description 68
- 238000012360 testing method Methods 0.000 claims description 66
- 206010018338 Glioma Diseases 0.000 claims description 65
- 208000032612 Glial tumor Diseases 0.000 claims description 64
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 63
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 63
- 238000003556 assay Methods 0.000 claims description 62
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 59
- 230000000391 smoking effect Effects 0.000 claims description 47
- 238000005259 measurement Methods 0.000 claims description 46
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 39
- 206010033128 Ovarian cancer Diseases 0.000 claims description 38
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 36
- 239000000047 product Substances 0.000 claims description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 33
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 32
- 239000011324 bead Substances 0.000 claims description 31
- 206010005003 Bladder cancer Diseases 0.000 claims description 30
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 30
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 30
- 230000004083 survival effect Effects 0.000 claims description 29
- 230000001973 epigenetic effect Effects 0.000 claims description 26
- 238000012549 training Methods 0.000 claims description 26
- 238000012175 pyrosequencing Methods 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 24
- 239000003298 DNA probe Substances 0.000 claims description 21
- 238000007847 digital PCR Methods 0.000 claims description 20
- 230000001404 mediated effect Effects 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 18
- 238000003753 real-time PCR Methods 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 17
- 230000003321 amplification Effects 0.000 claims description 16
- 210000004698 lymphocyte Anatomy 0.000 claims description 16
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 16
- 208000008589 Obesity Diseases 0.000 claims description 14
- 230000001506 immunosuppresive effect Effects 0.000 claims description 14
- 235000020824 obesity Nutrition 0.000 claims description 14
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 13
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 13
- 238000012544 monitoring process Methods 0.000 claims description 13
- 101150027879 FOXP3 gene Proteins 0.000 claims description 12
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 12
- 206010062016 Immunosuppression Diseases 0.000 claims description 12
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 12
- 201000010374 Down Syndrome Diseases 0.000 claims description 11
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 11
- 230000003247 decreasing effect Effects 0.000 claims description 11
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 11
- 108020003215 DNA Probes Proteins 0.000 claims description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 230000035945 sensitivity Effects 0.000 claims description 9
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 8
- 208000028782 Hereditary disease Diseases 0.000 claims description 8
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 8
- 208000024556 Mendelian disease Diseases 0.000 claims description 8
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000638 solvent extraction Methods 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000011325 microbead Substances 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 239000013068 control sample Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 229940035893 uracil Drugs 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 208000036878 aneuploidy Diseases 0.000 claims description 4
- 231100001075 aneuploidy Toxicity 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 239000010453 quartz Substances 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 208000017924 Klinefelter Syndrome Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 208000026928 Turner syndrome Diseases 0.000 claims description 2
- 230000002759 chromosomal effect Effects 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000013641 positive control Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 238000011002 quantification Methods 0.000 abstract description 21
- 238000003491 array Methods 0.000 abstract description 15
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 115
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 115
- 230000000694 effects Effects 0.000 description 59
- 239000013615 primer Substances 0.000 description 52
- 230000014509 gene expression Effects 0.000 description 48
- 210000005259 peripheral blood Anatomy 0.000 description 47
- 239000011886 peripheral blood Substances 0.000 description 47
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 44
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 42
- 230000000875 corresponding effect Effects 0.000 description 40
- 210000001519 tissue Anatomy 0.000 description 32
- 210000002865 immune cell Anatomy 0.000 description 31
- 238000002493 microarray Methods 0.000 description 26
- 108020004999 messenger RNA Proteins 0.000 description 24
- 238000004088 simulation Methods 0.000 description 23
- 239000013598 vector Substances 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000010200 validation analysis Methods 0.000 description 20
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 19
- 239000011159 matrix material Substances 0.000 description 19
- 238000013459 approach Methods 0.000 description 18
- 239000000090 biomarker Substances 0.000 description 18
- 238000000684 flow cytometry Methods 0.000 description 18
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 208000005017 glioblastoma Diseases 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 230000002611 ovarian Effects 0.000 description 15
- 238000011529 RT qPCR Methods 0.000 description 14
- 210000000601 blood cell Anatomy 0.000 description 14
- 235000019504 cigarettes Nutrition 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000011088 calibration curve Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000009897 systematic effect Effects 0.000 description 13
- 239000002987 primer (paints) Substances 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 206010003571 Astrocytoma Diseases 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000007477 logistic regression Methods 0.000 description 11
- 238000007619 statistical method Methods 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 9
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 230000002055 immunohistochemical effect Effects 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 238000010206 sensitivity analysis Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 8
- 241000701806 Human papillomavirus Species 0.000 description 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 7
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- 108010077544 Chromatin Proteins 0.000 description 6
- 108091029523 CpG island Proteins 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 6
- 241000341655 Human papillomavirus type 16 Species 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 201000010133 Oligodendroglioma Diseases 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 210000003483 chromatin Anatomy 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 238000013488 ordinary least square regression Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 206010014967 Ependymoma Diseases 0.000 description 5
- 102100038636 FYVE, RhoGEF and PH domain-containing protein 2 Human genes 0.000 description 5
- 101001031749 Homo sapiens FYVE, RhoGEF and PH domain-containing protein 2 Proteins 0.000 description 5
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 5
- 101000890749 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) F420-dependent hydroxymycolic acid dehydrogenase Proteins 0.000 description 5
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 5
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000007855 methylation-specific PCR Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 4
- 238000001134 F-test Methods 0.000 description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 4
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 4
- 101001023770 Homo sapiens Transcription factor NF-E2 45 kDa subunit Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 4
- 102100035412 Transcription factor NF-E2 45 kDa subunit Human genes 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 102100026293 Asialoglycoprotein receptor 2 Human genes 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 230000035131 DNA demethylation Effects 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 101000785948 Homo sapiens Asialoglycoprotein receptor 2 Proteins 0.000 description 3
- 238000001282 Kruskal–Wallis one-way analysis of variance Methods 0.000 description 3
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 3
- 238000012952 Resampling Methods 0.000 description 3
- 108091006750 SLC22A18 Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 102100023102 Solute carrier family 22 member 18 Human genes 0.000 description 3
- -1 Treg Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 229910052785 arsenic Inorganic materials 0.000 description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 238000007419 epigenetic assay Methods 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000001558 permutation test Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010845 search algorithm Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000012066 statistical methodology Methods 0.000 description 3
- 238000012109 statistical procedure Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 description 2
- 101000760638 Homo sapiens Protein ABHD16B Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102000047724 Member 2 Solute Carrier Family 12 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100024651 Protein ABHD16B Human genes 0.000 description 2
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 2
- 108091006621 SLC12A1 Proteins 0.000 description 2
- 108091006620 SLC12A2 Proteins 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000011304 droplet digital PCR Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000001909 effect on DNA Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000004906 toe nail Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- RKUAZJIXKHPFRK-UHFFFAOYSA-N 1,3,5-trichloro-2-(2,4-dichlorophenyl)benzene Chemical compound ClC1=CC(Cl)=CC=C1C1=C(Cl)C=C(Cl)C=C1Cl RKUAZJIXKHPFRK-UHFFFAOYSA-N 0.000 description 1
- 102100030389 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 Human genes 0.000 description 1
- 102100038511 AT-rich interactive domain-containing protein 3A Human genes 0.000 description 1
- 102100033757 Acyl-coenzyme A thioesterase 11 Human genes 0.000 description 1
- 102100026609 Aldehyde dehydrogenase family 3 member B1 Human genes 0.000 description 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108091005625 BRD4 Proteins 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 101150093947 CD3E gene Proteins 0.000 description 1
- 241001146702 Candidatus Entotheonella factor Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 102100025975 Cathepsin G Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241001327708 Coriaria sarmentosa Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101100379080 Emericella variicolor andB gene Proteins 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010022894 Euchromatin Proteins 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 206010053487 Exposure to toxic agent Diseases 0.000 description 1
- 102100035143 Folate receptor gamma Human genes 0.000 description 1
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 description 1
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000583066 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 Proteins 0.000 description 1
- 101000808887 Homo sapiens AT-rich interactive domain-containing protein 3A Proteins 0.000 description 1
- 101000801224 Homo sapiens Acyl-coenzyme A thioesterase 11 Proteins 0.000 description 1
- 101000717973 Homo sapiens Aldehyde dehydrogenase family 3 member B1 Proteins 0.000 description 1
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 description 1
- 101000933179 Homo sapiens Cathepsin G Proteins 0.000 description 1
- 101001023202 Homo sapiens Folate receptor gamma Proteins 0.000 description 1
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 description 1
- 101000746364 Homo sapiens Granulocyte colony-stimulating factor receptor Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001007022 Homo sapiens Keratin, type I cuticular Ha6 Proteins 0.000 description 1
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 description 1
- 101001014566 Homo sapiens Membrane-spanning 4-domains subfamily A member 3 Proteins 0.000 description 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
- 101000986836 Homo sapiens P2Y purinoceptor 2 Proteins 0.000 description 1
- 101001129851 Homo sapiens Paired immunoglobulin-like type 2 receptor alpha Proteins 0.000 description 1
- 101001002122 Homo sapiens Phospholemman Proteins 0.000 description 1
- 101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 description 1
- 101000974726 Homo sapiens Potassium voltage-gated channel subfamily E member 1 Proteins 0.000 description 1
- 101000632467 Homo sapiens Pulmonary surfactant-associated protein D Proteins 0.000 description 1
- 101001135826 Homo sapiens Serine/threonine-protein phosphatase 2A activator Proteins 0.000 description 1
- 101000847159 Homo sapiens Testis-specific gene 13 protein Proteins 0.000 description 1
- 101000794155 Homo sapiens Tetraspanin-16 Proteins 0.000 description 1
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 description 1
- 101000670973 Homo sapiens V-type proton ATPase subunit E 2 Proteins 0.000 description 1
- 101150082255 IGSF6 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022532 Immunoglobulin superfamily member 6 Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 102100028341 Keratin, type I cuticular Ha6 Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 description 1
- 102100032517 Membrane-spanning 4-domains subfamily A member 3 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100034559 Natural resistance-associated macrophage protein 1 Human genes 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 1
- 102100031651 Paired immunoglobulin-like type 2 receptor alpha Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100035969 Phospholemman Human genes 0.000 description 1
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 1
- 102100022755 Potassium voltage-gated channel subfamily E member 1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- 102100037257 Proton-associated sugar transporter A Human genes 0.000 description 1
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 108091006619 SLC11A1 Proteins 0.000 description 1
- 108091007562 SLC45A1 Proteins 0.000 description 1
- 102100036782 Serine/threonine-protein phosphatase 2A activator Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 102100032808 Testis-specific gene 13 protein Human genes 0.000 description 1
- 102100030159 Tetraspanin-16 Human genes 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 description 1
- CCAZWUJBLXKBAY-ULZPOIKGSA-N Tutin Chemical compound C([C@]12[C@@H]3O[C@@H]3[C@@]3(O)[C@H]4C(=O)O[C@@H]([C@H]([C@]32C)O)[C@H]4C(=C)C)O1 CCAZWUJBLXKBAY-ULZPOIKGSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102100039464 V-type proton ATPase subunit E 2 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000002678 cancer related effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000023437 ependymal tumor Diseases 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000000632 euchromatin Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000036397 gastrointestinal physiology Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 238000011493 immune profiling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000004959 laryngeal benign neoplasm Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000003910 liver physiology Effects 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030173 low grade glioma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 206010073131 oligoastrocytoma Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000023974 pharynx neoplasm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007319 proteasomal degradation pathway Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Analytical Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Molecular Biology (AREA)
- Data Mining & Analysis (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioethics (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Zoology (AREA)
- Artificial Intelligence (AREA)
- Software Systems (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des procédés faisant appel à des réseaux de méthylation d'ADN pour identifier une cellule ou un mélange de cellules et pour quantifier les modifications de distribution de cellules dans le sang ou dans les tissus, et pour diagnostiquer, pronostiquer et traiter des maladies, en particulier un cancer. Les procédés utilisent des échantillons fraîchement prélevés et stockés.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489883P | 2011-05-25 | 2011-05-25 | |
| US61/489,883 | 2011-05-25 | ||
| US201161509644P | 2011-07-20 | 2011-07-20 | |
| US61/509,644 | 2011-07-20 | ||
| US201261585892P | 2012-01-12 | 2012-01-12 | |
| US61/585,892 | 2012-01-12 | ||
| US201261619663P | 2012-04-03 | 2012-04-03 | |
| US61/619,663 | 2012-04-03 | ||
| PCT/US2012/039699 WO2012162660A2 (fr) | 2011-05-25 | 2012-05-25 | Procédés faisant appel à la méthylation de l'adn pour identifier une cellule ou un mélange de cellules afin de pronostiquer et de diagnostiquer des maladies et pour effectuer des traitements de réparation cellulaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2869295A1 true CA2869295A1 (fr) | 2012-11-29 |
Family
ID=47218125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2869295A Abandoned CA2869295A1 (fr) | 2011-05-25 | 2012-05-25 | Procedes faisant appel a la methylation de l'adn pour identifier une cellule ou un melange de cellules afin de pronostiquer et de diagnostiquer des maladies et pour effectuer des traitements de reparation cellulaire |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2714933A4 (fr) |
| CA (1) | CA2869295A1 (fr) |
| WO (1) | WO2012162660A2 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9561006B2 (en) * | 2008-10-15 | 2017-02-07 | The United States Of America As Represented By The Secretary Of The Navy | Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival |
| EP3382033B1 (fr) * | 2017-03-30 | 2020-08-05 | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen | Méthode pour déterminer le nombre des cellules sanguines basée sur la méthylation de l'adn |
| DE102017125019B4 (de) | 2017-10-25 | 2019-10-17 | Epiontis Gmbh | PDCD1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere PD1+ Zellen |
| DE102017125013B4 (de) | 2017-10-25 | 2019-10-17 | Epiontis Gmbh | MCC als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere basophiler Granulozyten |
| DE102017125150B4 (de) | 2017-10-26 | 2019-10-10 | Epiontis Gmbh | Endosialin (CD248) als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere naïver CD8+ T-Zellen |
| DE102017125335B4 (de) | 2017-10-27 | 2019-10-17 | Epiontis Gmbh | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten |
| DE102017126248B4 (de) | 2017-11-09 | 2019-10-17 | Epiontis Gmbh | ERGIC1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesonderemonozytischem myeloid-abgeleiteten Suppressor-Zellen (mMDSCs) |
| DE102018112644B4 (de) | 2018-05-25 | 2020-06-10 | Epiontis Gmbh | CXCR3 als epigenetischer Marker zur Identifizierung von inflammatorischen Immunzellen, insbesondere CD8+ Gedächnis-T-Zellen |
| EP3818179B1 (fr) | 2018-07-05 | 2023-07-19 | Precision for Medicine GmbH | Méthode épigénétique pour détecter et faire la distinction entre des syndromes ipex et des syndromes de type ipex, en particulier chez les nouveau-nés |
| DE102020108560B4 (de) | 2020-03-27 | 2022-03-03 | Precision For Medicine Gmbh | CBX6 als epigenetischer Marker für die Identifizierung von Immunzellen, insbesondere Gedächtnis-B-Zellen |
| DE102020111423B4 (de) | 2020-04-27 | 2022-03-03 | Precision For Medicine Gmbh | MYH11/NDE1 Region als epigenetischer Marker für die Identifizierung von Endothel-Vorläuferzellen (EPCs) |
| MX2023007012A (es) | 2020-12-14 | 2023-06-27 | Regeneron Pharma | Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe). |
| CN114703284A (zh) * | 2022-04-15 | 2022-07-05 | 北京莱盟君泰国际医疗技术开发有限公司 | 一种血液游离dna甲基化定量检测方法及其应用 |
| WO2024073508A2 (fr) * | 2022-09-27 | 2024-04-04 | Guardant Health, Inc. | Procédés et compositions de quantification d'adn de cellules immunitaires |
| CN116312794B (zh) * | 2023-01-09 | 2023-11-14 | 哈尔滨医科大学 | 一种融合单细胞分析方法的甲基化样本聚类方法 |
| DE102023114015B3 (de) | 2023-05-26 | 2024-09-12 | Precision For Medicine Gmbh | ITGA4 als epigenetischer Marker für die Identifizierung von Immunzellen |
| DE102023114016B3 (de) | 2023-05-26 | 2024-09-12 | Precision For Medicine Gmbh | LAG3 als epigenetischer Marker für die Identifizierung von Immunzellen |
| DE102023114004B3 (de) | 2023-05-26 | 2024-09-12 | Precision For Medicine Gmbh | GATA 3 als epigenetischer Marker zur Identifizierung von Immunzellen |
| DE102023114008B3 (de) | 2023-05-26 | 2024-09-12 | Precision For Medicine Gmbh | CRTH2 (PTGDR2) als epigenetischer Marker zur Identifizierung von Immunzellen |
| US20240410006A1 (en) * | 2023-06-12 | 2024-12-12 | Tru Diagnostics, Inc. | Method for Predicting Health of a Human Subject |
| CN116949156B (zh) * | 2023-09-19 | 2023-12-08 | 美迪西普亚医药科技(上海)有限公司 | 一种基于核酸变体的通用型检测人t细胞的分析方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070243161A1 (en) * | 2006-02-28 | 2007-10-18 | Sven Olek | Epigenetic modification of the loci for CAMTA1 and/or FOXP3 as a marker for cancer treatment |
| EP2199411B1 (fr) * | 2008-12-16 | 2015-05-06 | Epiontis GmbH | Marqueurs épigénétiques pour l'identification des lymphocytes T CD3+ |
-
2012
- 2012-05-25 EP EP12789375.8A patent/EP2714933A4/fr not_active Withdrawn
- 2012-05-25 CA CA2869295A patent/CA2869295A1/fr not_active Abandoned
- 2012-05-25 WO PCT/US2012/039699 patent/WO2012162660A2/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012162660A2 (fr) | 2012-11-29 |
| EP2714933A2 (fr) | 2014-04-09 |
| WO2012162660A3 (fr) | 2013-03-28 |
| EP2714933A4 (fr) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10619211B2 (en) | Methods using DNA methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies | |
| WO2012162660A2 (fr) | Procédés faisant appel à la méthylation de l'adn pour identifier une cellule ou un mélange de cellules afin de pronostiquer et de diagnostiquer des maladies et pour effectuer des traitements de réparation cellulaire | |
| Linge et al. | Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV (−) HNSCC after postoperative radiochemotherapy: a multicenter study of the DKTK-ROG | |
| ES2735993T3 (es) | Métodos para predecir el resultado clínico del cáncer | |
| Ouillette et al. | Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14 | |
| Linton et al. | Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours | |
| US11661632B2 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
| Poage et al. | Global hypomethylation identifies Loci targeted for hypermethylation in head and neck cancer | |
| US20110312520A1 (en) | Methods and compositions for diagnosing conditions | |
| US20100137164A1 (en) | Biomarkers for predicting prostate cancer progression | |
| US20190100809A1 (en) | Algorithms for disease diagnostics | |
| JP2008521412A (ja) | 肺癌予後判定手段 | |
| EP4163393B1 (fr) | Prédiction d'une réponse thérapeutique dans des états inflammatoires | |
| CN105981026A (zh) | 生物标志标识方法及用于其的装置和试剂盒 | |
| Zheng et al. | Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease | |
| US20120258878A1 (en) | Prognostic gene signatures for non-small cell lung cancer | |
| AU2012345789A1 (en) | Methods of treating breast cancer with taxane therapy | |
| CA2890161A1 (fr) | Combinaisons de biomarqueurs pour tumeurs colorectales | |
| Béné et al. | Leukemia diagnosis: today and tomorrow | |
| EP3207161A1 (fr) | Procédés et compositions pour mettre en corrélation des marqueurs génétiques avec le risque de cancer | |
| WO2019005764A1 (fr) | Génotype du cmh-i limitant le paysage mutationnel oncogène | |
| Kober et al. | DNA methylation pattern in somatotroph pituitary neuroendocrine tumors | |
| Morey et al. | Discovery and verification of extracellular microRNA biomarkers for diagnostic and prognostic assessment of preeclampsia at triage | |
| WO2014066984A1 (fr) | Procédé pour identifier un profil moléculaire cible associé à une population cellulaire cible | |
| US20210079479A1 (en) | Compostions and methods for diagnosing lung cancers using gene expression profiles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170524 |
|
| FZDE | Discontinued |
Effective date: 20210831 |